COVID-19: Can We Treat It? (Treat It?) No One Wants To Be Defeated!


Manage episode 295701351 series 2839375
由Player FM以及我们的用户群所搜索的Vital Statistics Consulting — 版权由出版商所拥有,而不是Player FM,音频直接从出版商的伺服器串流. 点击订阅按钮以查看Player FM更新,或粘贴收取点链接到其他播客应用程序里。

On this week's episode of the pod, we answer a question that we receive quite frequently: What are the current effective COVID-19 treatments?
We spend some time discussing how attempts have been made to repurpose existing medications for treatment which saves time rather than developing new ones from scratch. We kick things off with remdesivir-- the only FDA-approved treatment for adults and some children who require hospitalization. We discuss how remdesivir works and present some real-world evidence of its impact on mortality and time-to-discharge from the hospital. Next, we tackle monoclonal antibody treatments which have received emergency use authorization from the FDA to treat mild/moderate COVID-19 illness in adults and some older children. We discuss some other treatments (such as Baricitinib plus remdesivir) and Tocilizumab. We also discuss Dexamethasone and present some trial data on its use in improving mortality rates as compared to usual care. Next, we spend some time discussing nutritional supplements such as vitamin C, zinc, and particularly vitamin D which has received a lot of attention (mainly by supplement sellers). We briefly talk about the current status of ongoing clinical trials, using the oral antiviral Molnupiravir as an example. Next, we talk at length about Ivermectin and the mixed and weak evidence that has led the FDA, NIH, and WHO to conclude that there are insufficient data for the use of Ivermectin to treat COVID-19. Finally, we close the episode with a discussion of Hydroxychloroquine and the fact that clinical trials were halted early due to lack of effectiveness.
We are taking a break for the summer, but plan to come back with some exciting content in season 2! Stay safe, everyone!